Lippincott Nursing Pocket Card - November 2022
Alteplase (tissue plasminogen activator, recombinant; tPA) is approved by the U.S. FDA to treat acute ischemic stroke (AIS), acute myocardial infarction (AMI) to reduce mortality and incidence of heart failure, and acute massive pulmonary embolism (PE). Use the following drug information to increase your understanding of this agent and provide safe patient care.
Alteplase, given intravenously (IV), binds to fibrin in a thrombus and converts plasminogen to plasmin which initiates fibrinolysis. The initial half-life of alteplase is less than 5 minutes and it is cleared primarily through the liver.
Already a member? Sign in
© 2023 Wolters Kluwer Health, Inc. and/or its subsidiaries. All rights reserved. – Terms & Conditions – Privacy Policy – Disclaimer -- v08.09.00